AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06127147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IMT
Description: The IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc). The intensity of the training will be set to 60% of each patient's maximal inspiratory pressure.
Study NCT06127147 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-IMT
Description: The sham IMT protocol will consist of high-intensity daily training - 2 sets of 30 breaths with a 1-minute rest between sets, twice a day for 4 weeks using an IMT Threshold device (Threshold IMT Philips® Respironics, Inc) without intensity.
Study NCT05029310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Oral Product
Description: interaction study
Study NCT06289946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NitroBid
Description: We will apply nirobid to the wrist prior to left heart catheterization.
Study NCT06289946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We will apply placebo moisturizing cream to the wrist
Study NCT05930847 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Game Application
Description: The digital game contains brief information about the respiratory system adapted to children, and it is a game whose duration can be adjusted manually to follow the treatment process of the patient, taking into account the ½ ratio in the inhalation and exhalation process in the clinic.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Treatment period: Huaier Granule, oral administration, 10g each time, 3 times a day. Continuous medication until the end of the study, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment. After disease progression, whether to continue the medication or not should be determined by the researcher and patient together.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab + Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab + Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Apatinib
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab+Apatinib
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05930847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of medication for asthma
Description: The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
Study NCT05930847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of medication for asthma
Description: The children continued to take their current asthma medication on the same schedule. The drugs used by the children were zespira and ventolin.
Study NCT05384834 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #HerHeart tool
Description: An integrated application consisting of a lifestyle-based CVD risk assessment and companion behavioral intervention. It will be administered at baseline and 3 months follow-up.
Study NCT06319781 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: The study is a prospective non-interventional, observational study.
Study NCT04800744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender peppermint elequil aromatab
Description: Lavender peppermint elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
Study NCT04800744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sweet almond oil elequil aromatab
Description: Sweet almond oil elequil aromatab applied pre-operatively and every 12 hours thereafter for the duration of the 72 hour treatment window.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05660213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab+Bevacizumab
Description: Targeted Drug and Anti-PD-(L)1 antibody: Continuous medication until disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage.
Study NCT05274828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H7-Coil Deep TMS for CUD
Description: The Study group will receive dTMS treatment three times a day for ten days.
Study NCT05075707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromagnetic therapy.
Description: Electromagnetic therapy will be applied for 20 min/ session for (3 days/ week for two months) to the group intervention.
Study NCT05075707 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: Low level laser therapy (LLLT) will be applied for 20 min/session laser scanner for three days each week for two months to the group intervention.
Study NCT03924310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetBack System Active
Description: Commercially available hand prosthesis with feedback device turned on
Study NCT03924310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FeetBack System Passive
Description: Commercially available hand prosthesis with feedback device turned off
Study NCT06138028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
Description: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
Study NCT04759677 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with active video games
Description: 45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
Study NCT05493540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen oral suspension
Description: The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen
Study NCT05493540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen
Study NCT06511440 — intervention group
Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes
Study NCT04818541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPCI
Description: Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.
Study NCT04818541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Description: Closure of the femoral access site with PerQseal device after removal of the Impella pump.
Study NCT06446466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF ON-OFF
Description: In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session.
Study NCT06446466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF OFF-ON
Description: In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session.
Study NCT04836442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-PTSD-PFI (AP-PFI)
Description: Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
Study NCT06531369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil Injection（F1 group）
Description: Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
Study NCT06531369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil Injection（F2 group）
Description: Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.
Study NCT06531369 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline（C group）
Description: Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
Study NCT04836442 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Active Comparison Condition (C-PFI)
Description: Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
Study NCT06064292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSPIRATORY MUSCLE TRAINING
Description: After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
Study NCT05188053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution
Study NCT05188053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine , epinephrine , ketorolac diluted in sodium chloride
Description: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
Study NCT06450015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Assisted Closure
Description: VAC applied after debridement and saline packing
Study NCT06450015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Dressing
Description: Wound was managed by saline dressing
Study NCT05094245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block Group
Description: Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
Study NCT05237518 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense Noomi system
Description: The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
Study NCT06360315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive letter for pneumococcal vaccination to the patient and to the GP
Description: Incentive letter for pneumococcal vaccination to the patient and to the GP
Study NCT06258759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma supplement
Description: the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
Study NCT06258759 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: no autologous platelet-rich plasma supplement
Description: the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
Study NCT04532515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G Surgical Sealant
Description: Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Study NCT04532515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G MIST System
Description: Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Study NCT06187948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
Study NCT05499780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox
Description: The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
Study NCT05034341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free.
Study NCT05034341 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pre-Surgical Clinical Care
Description: * Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.
Study NCT06242002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Set up of sensor
Description: Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
Study NCT05518799 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: intravenous
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: intravenous
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: intravenous
Study NCT04861948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intravenous
Study NCT05578482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dicloxacillin Oral Capsule
Description: Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon
Study NCT05578482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon 0.1 % Topical Cream
Description: Both groups are treated with elocon for five days.
Study NCT05578482 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elocon 0.1 % Topical Cream
Description: Both groups are treated with elocon for five days.
Study NCT05652972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: 1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
Study NCT04597723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Patients will be given different concentrations of oxygen.
Study NCT06555536 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele OI
Description: A data collection and Telemedicine tool translated into an APP.
Study NCT05250882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced perioperative care protocol
Description: See arm/group description
Study NCT05649241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy patch
Study NCT05652972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control diet
Description: 1700 kcal standard diet (fat: protein: carbohydrate ratio of 20:30:50)
Study NCT05444985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management
Description: Regional anesthetic techniques for peri-operative pain management after surgery.
Study NCT05444985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Management
Description: Regional anesthetic techniques for peri-operative pain management after surgery.
Study NCT04880265 — intervention group
Intervention type: DEVICE
Intervention: BraveHeart wearable life sensors
Description: Collection of EKG data